$183 Million in Funding Set to Transform China’s Diagnostic Market

The Chinese government is spending money and writing policy to help local companies catch up with Western counterparts in sensors and diagnostics, says Lux Research

BOSTON--()--A sharply aging population with unmet medical needs is driving China’s government to invest in the rapid development of innovative sensing technologies, and emerging Chinese firms are gathering to challenge the more experienced Western players in the sensor and diagnostic market, says Lux Research.

The domestic industry today is relatively immature, with the current market structure dominated by Western companies and multinationals. However, the government is attempting to jump start a homegrown industry, with stated goals in the 12th Five Year Plan (FYP) of improving overall healthcare, especially in rural areas, and increasing funding in a number of key sensing and diagnostic research areas. In the 2011-2012 funding period, $82.9 million was award in molecular, biochemical, immunological, and physical diagnostic spaces, and China will spend an additional $103 million on basic research in the sector during the 12th FYP.

“A wide variety of innovative technologies are being developed at the university and research institute levels that are on par with research in more developed nations,” said Zhihao Yu, Lux Research Analyst and the lead author of the report titled, “The Emerging Diagnostic Landscape in China.” “Over the next three to five years, biologics-based diagnostics will catch up and offer strong domestic options to today’s imported Western technology.”

Lux Research analysts closely studied the diagnostic landscape in China and the potential impact from policy. Among their findings:

  • Chinese switching strategies. Domestic companies are shifting from a “me-too,” go-to-market strategy based on low cost production, to novel solutions requiring lengthy R&D cycles. In the $1.5 billion Chinese medical imaging market, Mindray, Wandong, and Neusoft have market share of 10% – and rising – based on sophisticated product development strategies.
  • High hopes on genomic sequencing. The Beijing Genomics Institute, claimed to be the world’s largest genome sequencing organization, is eyeing a big payoff by developing drugs specifically designed for Chinese and non-Caucasian populations, filling a gap left by U.S. drugmakers, based on recognized differences in response to marketed drugs between different populations.
  • R&D and policy driving growth. University research in China is finding its way into the business value chain. Beijing Largev Instrumentation, a developer of dental CT, was founded by Tsinghua University and Nuctech, and is a major player funded under the “key technologies and product development of major digital medical equipment” mandate for the 12th FYP.

The report, titled “The Emerging Diagnostic Landscape in China,” is part of the Lux Research China BioPharma Intelligence service.

About Lux Research

Lux Research provides strategic advice and ongoing intelligence for emerging technologies. Leaders in business, finance and government rely on us to help them make informed strategic decisions. Through our unique research approach focused on primary research and our extensive global network, we deliver insight, connections and competitive advantage to our clients. Visit www.luxresearchinc.com for more information.

Contacts

Lux Research, Inc.
Carole Jacques, 617-502-5314
carole.jacques@luxresearchinc.com

Release Summary

An aging population with unmet medical needs is driving China’s govt to invest in the fast development of innovative sensing technologies, w/ Chinese firms starting to make progress, says Lux Research

Sharing

Contacts

Lux Research, Inc.
Carole Jacques, 617-502-5314
carole.jacques@luxresearchinc.com